These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 15850334)

  • 41. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
    Yasuda T; Fukuda-Tani M; Nihira T; Wada K; Hattori N; Mizuno Y; Mochizuki H
    Exp Neurol; 2007 Aug; 206(2):308-17. PubMed ID: 17604022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Neuronal activities in the ventrolateral thalamus and basal ganglia in relation to Parkinson's disease].
    Wang J; Zhuang P; Li YJ
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(15):1021-6. PubMed ID: 16784702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.
    Mogi M; Kondo T; Mizuno Y; Nagatsu T
    Neurosci Lett; 2007 Feb; 414(1):94-7. PubMed ID: 17196747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain.
    Thompson LH; Grealish S; Kirik D; Björklund A
    Eur J Neurosci; 2009 Aug; 30(4):625-38. PubMed ID: 19674082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
    Nyholm D
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Agrawal AK
    Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats.
    Mukhida K; Hong M; Miles GB; Phillips T; Baghbaderani BA; McLeod M; Kobayashi N; Sen A; Behie LA; Brownstone RM; Mendez I
    Brain; 2008 Aug; 131(Pt 8):2106-26. PubMed ID: 18669492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Death of dopaminergic neurones in the rat substantia nigra can be induced by damage to globus pallidus.
    Wright AK; Atherton JF; Norrie L; Arbuthnott GW
    Eur J Neurosci; 2004 Oct; 20(7):1737-44. PubMed ID: 15379994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resurgence of functional neurosurgery for Parkinson's disease: a historical perspective.
    Speelman JD; Bosch DA
    Mov Disord; 1998 May; 13(3):582-8. PubMed ID: 9613759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anatomy and physiology of the basal ganglia: implications for deep brain stimulation for Parkinson's disease.
    Kopell BH; Rezai AR; Chang JW; Vitek JL
    Mov Disord; 2006 Jun; 21 Suppl 14():S238-46. PubMed ID: 16810674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The basal ganglia in Parkinson's disease: current concepts and unexplained observations.
    Obeso JA; Marin C; Rodriguez-Oroz C; Blesa J; Benitez-Temiño B; Mena-Segovia J; Rodríguez M; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S30-46. PubMed ID: 19127584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
    Marek K; Jennings D; Seibyl J
    Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
    [No Abstract]   [Full Text] [Related]  

  • 56. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
    Joyce JN; Millan MJ
    Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
    Elsworth JD; Roth RH
    Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
    Liu WG; Lu GQ; Li B; Chen SD
    Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.